Bavarian Nordic (OTCMKTS:BVNRY) Shares Up 4% – Here’s Why

Bavarian Nordic (OTCMKTS:BVNRY)’s share price shot up 4% during mid-day trading on Thursday. The company traded as high as $11.1150 and last traded at $11.1150. 510 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 3,230 shares. The stock had previously closed at $10.69.

Bavarian Nordic Price Performance

The firm has a market capitalization of $2.63 billion, a PE ratio of 11.15 and a beta of 1.20. The company’s fifty day simple moving average is $10.11 and its 200 day simple moving average is $9.83.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. The firm had revenue of $316.47 million during the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.

Bavarian Nordic Company Profile

Bavarian Nordic A/S (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and commercializes vaccines for infectious diseases. The company serves government agencies, military organizations, healthcare providers and travelers, with products distributed across Europe, North America and other international markets.

Its best-known product is JYNNEOS, also marketed as IMVAMUNE or IMVANEX in certain regions, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for rabies and tick-borne encephalitis, including RabAvert and Rabipur for rabies prevention and Encepur for protection against tick-borne encephalitis.